Hollings Horizons Winter/Spring 2026 - Magazine - Page 4
Director’s
Message
MUSC Hollings Cancer Center holds a unique responsibility
as South Carolina’s only NCI-designated cancer center.
Our mission is threefold: providing exceptional patient care,
advancing cancer research in our laboratories, and training the
next generation of scientists and clinicians.
At Hollings, patients have access to more than 200 clinical
trials, ranging from studies on smoking cessation to trials of
innovative cancer therapies. These include trials developed by
our own physicians in response to challenges they see in the
clinic, as well as those led by pharmaceutical companies and
national academic research groups. Through these efforts, we
offer patients new treatment options while contributing to the
scientific discoveries that shape tomorrow’s standards of care.
As you’ll see in these pages, we are expanding across South
Carolina with new facilities, programs, and physicians to meet
the state’s growing health care needs. Our plans include
a best-in-class cancer hospital in downtown Charleston bringing inpatient and outpatient services under one roof
- slated for completion in 2030, along with a new integrated
Center for Cellular Therapy.
Our vision is clear: to reduce cancer incidence and mortality
across South Carolina. This work is challenging, but it is
profoundly rewarding and deeply meaningful. I extend my
heartfelt thanks to our dedicated staff, physicians, scientists,
and supporters for being an essential part of this mission.
Raymond N. DuBois, M.D., Ph.D.
Director, MUSC Hollings Cancer Center
Associate Provost of Cancer Programs, MUSC
2
Hollings Horizons Winter/Spring 2026
